Mobile Contingency Management for Marijuana and Tobacco Cessation

Mobile Contingency Management for Concurrent Abstinence From Cannabis and Cigarette Smoking: A Pilot Study

The purpose of this pilot project is to pilot-test a combined cannabis and smoking cessation treatment. The intervention combines mobile technology with behavioral strategies, counseling, and medications.

Study Overview

• Status: Completed
• Conditions: Marijuana Abuse; Cigarette Smoking
• Intervention / Treatment: Drug: bupropion; Drug: transdermal nicotine patch; Drug: Nicotine polacrilex; Drug: nicotine lozenge; Behavioral: counseling for marijuana and smoking cessation; Behavioral: mobile contingency management

Detailed Description

Cannabis is the most widely used illicit drug in the United States with 19.8 million current users. Population based data indicate that almost all cannabis users (90%) have a lifetime history of tobacco smoking and the majority (74%) currently smoke tobacco. While cannabis use alone is associated with significant adverse health effects, tobacco smoking is the number one preventable cause of illness and death in the U.S. This is true even among those using illicit drugs where the tobacco -related mortality rate is twice that of the general population. Among cannabis users, smoking tobacco is associated with increased frequency of marijuana use, increased morbidity, and poorer cannabis cessation outcomes. There is strong evidence for the short -term efficacy for cannabis use disorder (CUD) and smoking of contingency management (CM). It is an intensive behavioral therapy that provides incentives (vouchers, money) to individuals misusing substances contingent upon objective evidence from drug use. Implementation of CM has been limited because of the need to verify abstinence multiple times daily using clinic based monitoring and effects are short lived. The investigators recently developed a smart -phone application which allows a patient to video themselves several times daily while using a small CO monitor and to transmit the data to a secure server which has made the use of CM for outpatient smoking cessation portable and feasible. The mobile CM (mCM) approach paired with cognitive-behavioral counseling and pharmacological smoking cessation aids has been effective in reducing smoking in the short and long-term. The purpose of this pilot project is to pilot-test a combined cannabis and smoking mCM intervention. The pilot will allow the investigators to examine feasibility of the treatment and of planned recruitment strategies. These project aims will provide the first step toward implementation of an innovative approach that builds upon the power of mHealth technology to reduce the prevalence of both CUD and cigarette smoking.

• Study Type: Interventional
• Enrollment (Actual): 7
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • North Carolina
    • Durham, North Carolina, United States, 27706
      • Duke University Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• report 40 or more days of cannabis use in the past 90 day;
• have smoked at least seven cigarettes in the past seven days;
• have been smoking for at least the past year;
• can speak and write fluent conversational English;
• are between 18 and 70 years of age; and
• are willing to make an attempt to quit both cannabis and tobacco smoking.

Exclusion Criteria:

• expected to have unstable medication regimen during the study;
• currently receiving non-study behavioral treatment for cannabis use disorder or smoking;
• myocardial infarction in past six months;
• contraindication to NRT with no medical clearance;
• use of other forms of nicotine such as cigars, pipes, or chewing tobacco with unwillingness to stop use of these forms;
• current pregnancy;
• primary psychotic disorder or current manic episode;
• substance use disorder (other than cannabis or nicotine) within the preceding three months; or
• current imprisonment or psychiatric hospitalization.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Treatment; Cognitive-behavioral counseling for marijuana and smoking cessation, mobile contingency management for marijuana and smoking cessation, transdermal nicotine patch (7-21 mg over six weeks), nicotine polacrilex or nicotine lozenge (4 mg administered as needed over six weeks), bupropion (150 mg once per day for 7 days, then 150 mg twice per day for about six months.

Drug: bupropion; Prescribed one week prior to quit and continued until the 6 month follow-up visit.; Other Names: Zyban; Drug: transdermal nicotine patch; Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant; Drug: Nicotine polacrilex; Initiated at smoking quit date.; Other Names: nicotine gum; nicorette; Drug: nicotine lozenge; Initiated at smoking quit date.; Behavioral: counseling for marijuana and smoking cessation; 5 sessions of cognitive-behavioral counseling designed to facilitate marijuana and smoking cessation and promote relapse prevention; Behavioral: mobile contingency management; treatment that provides money rewards for abstinence from smoking and marijuana

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants Who Self-report Prolonged Abstinence From Smoking	Participants self-report smoking behavior since smoking quit date. Prolonged abstinence is defined as sustained abstinence since two weeks post-initial smoking quit date.	6 month follow up
Number of Participants Who Report Smoking Abstinence and Abstinence is Bioverified by Salivary Cotinine	Self-reported abstinence (primary outcome) will be verified by cotinine assay. Saliva samples will be collected from participants who self-report prolonged abstinence.	6 month follow up
Number of Participants Who Self-report Prolonged Abstinence From Marijuana Use	Participants self-report marijuana use since marijuana quit date. Prolonged abstinence is defined as sustained abstinence since two weeks post-initial quit date.	6 month follow up
Number of Participants Who Report Marijuana Abstinence and Abstinence is Bioverified by Oral Fluid	Self-reported abstinence (primary outcome) will be verified by oral fluid (OF) cannabis assessment. Oral fluid samples will be collected from participants who self-report prolonged abstinence.	6 month follow up

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants Who Self-report 7 Day Point Prevalence Abstinence From Smoking	7-day point prevalence abstinence is defined as no smoking in the prior 7 days.	6 month follow up
Number of Participants Who Report 30 Day Point Prevalence Abstinence From Smoking	30-day point prevalence abstinence is defined as no smoking in the prior 30 days.	6 month follow up
Number of Participants Who Report 7 Day Point Prevalence Abstinence From Smoking	7-day point prevalence abstinence is defined as no smoking in the prior 7 days.	3 month follow up
Number of Participants Who Self-report 7 Day Point Prevalence Abstinence From Marijuana	7-day point prevalence abstinence is defined as no marijuana use in the prior 7 days.	6 month follow up
Number of Participants Who Report 30 Day Point Prevalence Abstinence From Marijuana	30-day point prevalence abstinence is defined as no marijuana use in the prior 30 days.	6 month follow up
Number of Participants Who Report 7 Day Point Prevalence Abstinence From Marijuana	7-day point prevalence abstinence is defined as no marijuana use in the prior 7 days.	3 month follow up
Number of Participants Who Report Smoking Abstinence and Abstinence is Bioverified by Salivary Cotinine	Self-reported abstinence (primary outcome) will be verified by cotinine assay. Saliva samples will be collected from participants who self-report prolonged abstinence.	3 month follow up
Number of Participants Who Report Marijuana Abstinence and Abstinence is Bioverified by Salivary Cotinine	Self-reported abstinence (primary outcome) will be verified by oral fluid (OF) cannabis assessment. Oral fluid samples will be collected from participants who self-report prolonged abstinence.	3 month follow up
Change From Baseline in Number of Days Per Week of Cannabis Use	Participants will self-report amount of marijuana used in past week; this will be compared to self-reported amount smoked per week prior to quit date.	baseline, 6 month follow up
Proportional Change in Days of Cannabis Use From Pre-quit to 6 Month Follow-up (Entire Group)	Participants will self-report number of days marijuana used in the past 30 days and this will be compared for the entire group to self-reported number of days of use in 30 days prior to quit. The proportion will be calculated by totaling baseline days used and pretreatment days used, and then dividing baseline days used by pretreatment days used.	30 days prior to quit date, 6 month follow up
Change in Number of Cigarettes Smoked Per Week Compared to Pre-quit	Self-reported number of cigarettes smoked each day in past 7 days; this will be compared to self-reported amount smoked in week prior to quit date	7 days prior to quit date, 6 month follow up
Proportional Change in Days Smoked From Pre-quit to 6-month Follow up (for Entire Group)	Participants will self-report number of days smoked in the past 30 days and this will be compared (for the entire group) to self-reported number of days smoked in 30 days prior to quit. The proportion will be calculated by totaling baseline days used and pretreatment days used, and then dividing baseline days used by pretreatment days used.	30 days prior to quit date, 6 month follow up
Percentage of Missing Mobile Contingency Management Video Recordings	Participants upload video recordings of abstinence verification as part of contingency management treatment. Percentage of missed videos (compared to expected videos) will be assessed as a measure of feasibility of the contingency management intervention	3 month follow up
Number of Missed Behavioral Counseling Sessions	Participants attend telephone counseling sessions. Number of missed sessions for the total group will be assessed as a measure of acceptability of the behavioral counseling	3 month follow up
Number of Voluntary Withdrawals From the Project	The number of participants who withdraw from the study will be evaluated as a measure of treatment feasibility and acceptability	Evaluated at 6 month follow-up

Collaborators and Investigators

• Sponsor: Duke University
• Investigators: Principal Investigator: Jean C Beckham, Ph.D., Study Principal Investigator

Study record dates

Study Major Dates

• Study Start (Actual): August 1, 2016
• Primary Completion (Actual): May 17, 2017
• Study Completion (Actual): May 17, 2017

Study Registration Dates

• First Submitted: August 8, 2016
• First Submitted That Met QC Criteria: August 15, 2016
• First Posted (Estimate): August 17, 2016

Study Record Updates

• Last Update Posted (Actual): February 7, 2020
• Last Update Submitted That Met QC Criteria: January 28, 2020
• Last Verified: January 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Chemically-Induced Disorders; Substance-Related Disorders; Marijuana Abuse; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Autonomic Agents; Peripheral Nervous System Agents; Cholinergic Agents; Enzyme Inhibitors; Psychotropic Drugs; Neurotransmitter Uptake Inhibitors; Membrane Transport Modulators; Antidepressive Agents; Dopamine Agents; Cytochrome P-450 Enzyme Inhibitors; Ganglionic Stimulants; Nicotinic Agonists; Cholinergic Agonists; Antidepressive Agents, Second-Generation; Cytochrome P-450 CYP2D6 Inhibitors; Dopamine Uptake Inhibitors; Nicotine; Bupropion
• Other Study ID Numbers: Pro00072366

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO